Bone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseBone MarrowWhole-Body IrradiationTissue DonorsBone Marrow CellsTransplantation ConditioningLeukemiaGraft SurvivalAnemia, AplasticHistocompatibility TestingTransplantation, AutologousTransplantation ChimeraHistocompatibilityHematopoietic Stem Cell TransplantationBusulfanLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukocyte TransfusionKidney TransplantationRecurrenceGraft vs Tumor EffectImmunosuppressive AgentsLiving DonorsRadiation ChimeraGraft RejectionLeukemia, Myeloid, AcuteGraft vs Host ReactionPrecursor Cell Lymphoblastic Leukemia-LymphomaHematologic NeoplasmsCyclophosphamideLymphocyte DepletionRemission InductionGraft vs Leukemia EffectTreatment OutcomeTransplantation, IsogeneicAcute DiseaseTime FactorsBone and BonesLymphocyte TransfusionHepatic Veno-Occlusive DiseaseImmunosuppressionLeukemia, MyeloidBone Marrow PurgingMice, Inbred C57BLCombined Modality TherapyHematopoietic Stem CellsChimeraRetrospective StudiesT-LymphocytesCyclosporineSurvival AnalysisTransplantation ImmunologyMyelodysplastic SyndromesLiver TransplantationNuclear FamilyHematopoiesisCytomegalovirus InfectionsTissue and Organ ProcurementHLA AntigensActuarial AnalysisSurvival RateAntilymphocyte SerumFatal OutcomeHematologic DiseasesMice, Inbred BALB CLymphoma, Non-HodgkinSevere Combined ImmunodeficiencyCadaverCytarabineFollow-Up StudiesDirected Tissue DonationBone Marrow DiseasesHeart TransplantationAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalSpleenPancytopeniaGranulocyte Colony-Stimulating FactorLeukocyte CountInfectionStem Cell TransplantationLeukemia, Myelomonocytic, AcuteAnemia, Refractory, with Excess of BlastsImmunocompromised HostBlood DonorsMethotrexateGanciclovirLymphomaBone Marrow ExaminationEtoposideLung TransplantationCyclosporinsNeoplasm, ResidualFlow CytometryMultiple MyelomaPrognosisUnrelated DonorsIsoantigensBone Remodeling